| Literature DB >> 12772783 |
Yasuji Komorizono1, Kazunori Kohara, Makoto Oketani, Masahiko Maeda, Toshihiko Shibathou, Shuhou Shigenobu, Yasusi Hiramine, Naruhiro Yamasaki, Takushi Arima, Ishibashi Kazuaki, Terukatsu Arima.
Abstract
The purpose of this pilot study was to evaluate the efficacy and adverse events of systemic combined chemotherapy with low dose of 5-fluorouracil (250 mg/m2, 5 days), cisplatin (10 mg/m2, 5 days), and interferon-alpha (2.5 million units, three times weekly) for advanced hepatocellular carcinoma (HCC) underlying liver cirrhosis. Six patients who had advanced HCC with tumor thrombi in the main portal trunk were enrolled in this study. Partial response was achieved in 2, stable disease in 1, and disease progressed in 3. Objective responses were achieved in 2 (33%), however, marked decreases of alpha-fetoprotein protein and protein-induced vitamin K antagonist or absence (PIVKAII) levels were also seen in one patient (stable disease). Four patients showed hematologic or renal toxicity, which were well tolerated and managed. Our systemic combined chemotherapy resulted in favorable response and was well tolerated in those with advanced HCC underlying liver cirrhosis, complicated by leukocytopenia and thromobocytopenia.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12772783 DOI： 10.1023/a:1023035109665
Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199